Intellia Therapeutics, Inc. (NASDAQ:NTLA) Expected to Announce Quarterly Sales of $8.60 Million

Wall Street brokerages expect Intellia Therapeutics, Inc. (NASDAQ:NTLA) to report sales of $8.60 million for the current quarter, Zacks Investment Research reports. Eight analysts have provided estimates for Intellia Therapeutics’ earnings, with the lowest sales estimate coming in at $4.67 million and the highest estimate coming in at $15.22 million. Intellia Therapeutics posted sales of $22.22 million during the same quarter last year, which would indicate a negative year over year growth rate of 61.3%. The company is scheduled to announce its next quarterly earnings results on Thursday, November 4th.

On average, analysts expect that Intellia Therapeutics will report full-year sales of $30.49 million for the current fiscal year, with estimates ranging from $13.00 million to $49.99 million. For the next financial year, analysts anticipate that the firm will report sales of $43.22 million, with estimates ranging from $22.80 million to $70.00 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Intellia Therapeutics.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by ($0.40). Intellia Therapeutics had a negative return on equity of 39.01% and a negative net margin of 442.58%. The company had revenue of $6.55 million for the quarter, compared to analyst estimates of $12.21 million. During the same period in the prior year, the business earned ($0.61) earnings per share. Intellia Therapeutics’s revenue was down 59.7% on a year-over-year basis.

Several equities analysts have recently issued reports on the company. Chardan Capital reaffirmed a “buy” rating and set a $177.00 price target on shares of Intellia Therapeutics in a research note on Thursday, September 16th. Wedbush upped their price objective on Intellia Therapeutics from $73.00 to $87.00 and gave the company a “neutral” rating in a report on Monday, June 28th. They noted that the move was a valuation call. HC Wainwright reissued a “buy” rating and issued a $171.00 target price on shares of Intellia Therapeutics in a report on Monday, September 13th. Jefferies Financial Group upped their target price on Intellia Therapeutics from $83.00 to $109.00 and gave the stock a “buy” rating in a report on Tuesday, June 22nd. Finally, Zacks Investment Research raised shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday. Four analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $146.50.

Intellia Therapeutics stock traded up $6.27 during mid-day trading on Monday, hitting $131.62. 26,922 shares of the company’s stock were exchanged, compared to its average volume of 1,630,194. The stock has a market cap of $9.67 billion, a P/E ratio of -46.47 and a beta of 2.14. The stock has a 50 day moving average of $151.06 and a two-hundred day moving average of $115.14. Intellia Therapeutics has a 1-year low of $22.17 and a 1-year high of $202.73.

In other news, EVP Laura Sepp-Lorenzino sold 26,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 4th. The shares were sold at an average price of $138.24, for a total transaction of $3,594,240.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP David Lebwohl sold 2,400 shares of the business’s stock in a transaction that occurred on Monday, August 9th. The shares were sold at an average price of $164.05, for a total value of $393,720.00. Following the completion of the transaction, the executive vice president now directly owns 3,191 shares in the company, valued at approximately $523,483.55. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 294,803 shares of company stock worth $45,679,690. 3.90% of the stock is owned by insiders.

Large investors have recently bought and sold shares of the business. Advisory Services Network LLC purchased a new stake in shares of Intellia Therapeutics in the second quarter valued at $32,000. Itau Unibanco Holding S.A. acquired a new position in Intellia Therapeutics in the second quarter worth about $47,000. Sterling Investment Advisors Ltd. bought a new position in shares of Intellia Therapeutics in the 2nd quarter worth about $49,000. Rockefeller Capital Management L.P. increased its position in Intellia Therapeutics by 67.8% in the first quarter. Rockefeller Capital Management L.P. now owns 626 shares of the company’s stock worth $50,000 after buying an additional 253 shares during the period. Finally, Bbva USA bought a new position in Intellia Therapeutics in the 2nd quarter worth approximately $77,000. Hedge funds and other institutional investors own 84.32% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.

Further Reading: Capital gains and your 401(k) or IRA

Get a free copy of the Zacks research report on Intellia Therapeutics (NTLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.